These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32267807)

  • 61. The role of stigma in U.S. primary care physicians' treatment of opioid use disorder.
    Stone EM; Kennedy-Hendricks A; Barry CL; Bachhuber MA; McGinty EE
    Drug Alcohol Depend; 2021 Apr; 221():108627. PubMed ID: 33621805
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The Impact on Future Prescribing Patterns of Opioid Use Disorder (OUD) Education and Waiver Provision During Residency.
    Boggiano V; Gilmore Wilson C; Fagan EB; Kirk J; Bossenbroek-Fedoriw K; Tak CR
    J Am Board Fam Med; 2020; 33(6):998-1003. PubMed ID: 33219079
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Implementation of buprenorphine initiation and warm handoff protocols in emergency departments: A qualitative study of Pennsylvania hospitals.
    Patel E; Solomon K; Saleem H; Saloner B; Pugh T; Hulsey E; Leontsini E
    J Subst Abuse Treat; 2022 May; 136():108658. PubMed ID: 34774397
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Attitudes on Methadone Utilization in the Emergency Department: A Physician Cross-sectional Study.
    Heil J; Ganetsky VS; Salzman MS; Hunter K; Baston KE; Carroll G; Ketcham E; Haroz R
    West J Emerg Med; 2022 Apr; 23(3):386-395. PubMed ID: 35679506
    [TBL] [Abstract][Full Text] [Related]  

  • 66. County-level access to opioid use disorder medications in medicare Part D (2010-2015).
    Abraham AJ; Adams GB; Bradford AC; Bradford WD
    Health Serv Res; 2019 Apr; 54(2):390-398. PubMed ID: 30665272
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Buprenorphine prescribing practice trends and attitudes among New York providers.
    Kermack A; Flannery M; Tofighi B; McNeely J; Lee JD
    J Subst Abuse Treat; 2017 Mar; 74():1-6. PubMed ID: 28132694
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Trends in and Characteristics of Buprenorphine Misuse Among Adults in the US.
    Han B; Jones CM; Einstein EB; Compton WM
    JAMA Netw Open; 2021 Oct; 4(10):e2129409. PubMed ID: 34652446
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Treatment access for opioid use disorder in pregnancy among rural and American Indian communities.
    Kelley AT; Smid MC; Baylis JD; Charron E; Begaye LJ; Binns-Calvey A; Archer S; Weiner S; Pettey W; Cochran G
    J Subst Abuse Treat; 2022 May; 136():108685. PubMed ID: 34953636
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The Community-Based Medication-First program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State.
    Banta-Green CJ; Owens MD; Williams JR; Sears JM; Floyd AS; Williams-Gilbert W; Kingston S
    Addict Sci Clin Pract; 2022 Jul; 17(1):34. PubMed ID: 35799210
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Medication-Assisted Treatment for Opioid Use Disorder in a Rural Family Medicine Practice.
    Deyo-Svendsen M; Cabrera Svendsen M; Walker J; Hodges A; Oldfather R; Mansukhani MP
    J Prim Care Community Health; 2020; 11():2150132720931720. PubMed ID: 32507023
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The case for a medication first approach to the treatment of opioid use disorder.
    Winograd RP; Presnall N; Stringfellow E; Wood C; Horn P; Duello A; Green L; Rudder T
    Am J Drug Alcohol Abuse; 2019; 45(4):333-340. PubMed ID: 31084515
    [No Abstract]   [Full Text] [Related]  

  • 73. Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014.
    Hadland SE; Wharam JF; Schuster MA; Zhang F; Samet JH; Larochelle MR
    JAMA Pediatr; 2017 Aug; 171(8):747-755. PubMed ID: 28628701
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Hospital Buprenorphine Program for Opioid Use Disorder Is Associated With Increased Inpatient and Outpatient Addiction Treatment.
    Christian N; Bottner R; Baysinger A; Boulton A; Walker B; Valencia V; Moriates C
    J Hosp Med; 2021 Jun; 16(6):345-348. PubMed ID: 34129485
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Sharp decline in hospital and emergency department initiated buprenorphine for opioid use disorder during COVID-19 state of emergency in California.
    Herring AA; Kalmin M; Speener M; Goodman-Meza D; Snyder H; Campbell A; Moulin A; Shoptaw S
    J Subst Abuse Treat; 2021 Apr; 123():108260. PubMed ID: 33612194
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Ensuring buprenorphine access in rural community pharmacies to prevent overdoses.
    Ostrach B; Potter R; Wilson CG; Carpenter D
    J Am Pharm Assoc (2003); 2022; 62(2):588-597.e2. PubMed ID: 34674965
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Overcoming Barriers to Prescribing Buprenorphine for the Treatment of Opioid Use Disorder: Recommendations from Rural Physicians.
    Andrilla CHA; Moore TE; Patterson DG
    J Rural Health; 2019 Jan; 35(1):113-121. PubMed ID: 30339720
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Nudging Emergency Department-Initiated Addiction Treatment.
    Butler K; Chavez T; Wakeman S; Robertson T; Leifer J; Barofsky J; Kao LS; Lefkowitz J; Dutta S; Hayes B; White B; Raja A; Martin A
    J Addict Med; 2022 Jul-Aug 01; 16(4):e234-e239. PubMed ID: 34775439
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Impact of treatment duration on mortality among Veterans with opioid use disorder in the United States Veterans Health Administration.
    Ching JH; Owens DK; Trafton JA; Goldhaber-Fiebert JD; Salomon JA
    Addiction; 2021 Dec; 116(12):3494-3503. PubMed ID: 33999485
    [TBL] [Abstract][Full Text] [Related]  

  • 80. "I'm a Survivor": Perceptions of Chronic Disease and Survivorship Among Individuals in Long-Term Remission from Opioid Use Disorder.
    Pytell JD; Sklar MD; Carrese J; Rastegar DA; Gunn C; Chander G
    J Gen Intern Med; 2022 Feb; 37(3):593-600. PubMed ID: 34027611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.